A predictive tool for determining the age at which individuals may develop mild cognitive impairment (MCI) or Alzheimer's ...

Alzheimer's disease begins with a long period during which abnormal amyloid and tau proteins build up in the brain without ...

The Alzheimer’s disease market is expected to grow at a CAGR of 23.4% from $2.4bn in 2023 to $19.3bn by 2033 across the 8MM ...

Posdinemab is an investigational monoclonal antibody that targets the mid-domain of Alzheimer's disease-specific ...

The Phase Ia trial is designed to assess the company’s drug designed to target chemicals thought to be a cause of Alzheimer’s disease.

Posdinemab works by targeting and neutralizing Alzheimer disease-specific phosphorylated tau, preventing its spread to other neurons.

For decades, scientists have been trying to develop therapeutics for people living with Alzheimer’s disease, a progressive ...

Building on decades of the Company's Alzheimer's research, two differentiated investigational therapies aim to slow pathological tau in distinct populations Fast Track designations reinforce J&J's ...

GlobalData analysis suggests that China will lead with the highest number of prevalent cases of Alzheimer’s disease in 2033.

GROUNDBREAKING research has shown that chronic intestinal infections caused by cytomegalovirus (HCMV) may play a role in a ...

Targeting toxic oligomers without binding to plaque, designed to reduce the risk of ARIA and potentially deliver enhanced outcomes for patients ...